Hyponatremia medical therapy

Hyponatremia Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hyponatremia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiogram or Ultarsound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hyponatremia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hyponatremia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hyponatremia medical therapy
CDC on Hyponatremia medical therapy
Hyponatremia medical therapy in the news
Blogs on Hyponatremia medical therapy
Directions to Hospitals Treating hyponatremia
Risk calculators and risk factors for Hyponatremia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Saeedeh Kowsarnia M.D.[2]

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

Hyponatremia must be corrected slowly in order to lessen the chance of the development of central pontine myelinolysis (CPM), a severe neurological disease. In fact, overly rapid correction of hyponatremia is the most common cause of that potentially devastating disorder. During treatment of hyponatremia, the serum sodium should not be allowed to rise by more than 8 mmol/l over 24 hours (i.e. 0.33 mmol/l/h rate of rise). In practice, too rapid correction of hyponatremia and thence CPM is most likely to occur during the treatment of hypovolemic hyponatremia. In particular, once the hypovolemic state has been corrected, the signal for ADH release disappears. At that point, there will be an abrupt water diuresis (since there is no longer any ADH acting to retain the water). A rapid and profound rise in serum sodium can then occur. Should the rate of rising of serum sodium exceed 0.33  mmol/l/h over several hours, vasopressin may be administered to prevent ongoing rapid water diuresis.

Treatment based on the conditions :

Conditions	Treatment
Pseudohyponatremia	Hyperglycemia: Insulin, IV fluids, isotonic saline Hyperproteinemia: Chemotherapy( Multiple myeloma), Stop IVIG Hyperglycemia: Statin therapy Lab error: Repeat the test
Hypovolemic Hyponatremia	Gastrointestinal loss:Intravenous fluids Renal loss Osmotic diuresis: Correct glucose level, stop mannitol use Renal tubular acidosis : Correct acidosis, sodium bicarbonate Salt-wasting nephropathies : Correct underlying cause Diuretic use : Stop diuretic therapy Mineralocorticoid deficiency : Steroid replacement therapy, isotonic saline Third spacing : Intravenous fluids, treat the underlying cause Cerebral salt-wasting syndrome : Isotonic or hypertonic saline, fludrocortisone rarely
Hypervolemic hyponatremia	Heart failure : Diuretics, angiotensin-converting enzyme inhibitors, beta blockers, vaptans Hepatic failure/cirrhosis : Furosemide (Lasix), spironolactone (Aldactone), transplant, vaptans (not tolvaptan for cirrhosis) Renal failure (acute or chronic),Nephrotic syndrome : Correct underlying disease with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,treat underlying cause for nephrotic syndrome
Euvolemic Hyponatremia	Drugs : Stop causative medications SIADH/SIAD : Fluid restriction, demeclocycline, consider vaptans (second line), oral salt tablets, urea Nephrogenic SIAD : Fluid restriction, loop diuretics, oral salt tablets, urea Hight fluid intake : Diuresis Hypothyriodism : Thyroid replacement therapy Glucocorticoid deficiency : Steroid replacement therapy Reset osmostat : Treat underlying disease
Rate of correction	Goal: Raise the serum sodium concentration by 4 to 6 mEq/L in a 24-hour period Maximum: Should be ≤ 8 mEq/L in any 24-hour period, pediatric: rates ≤ 9 mEq/ L
Acute hyponatremia	For severe symptoms : Adult: 100 mL of 3% saline (NaCl) infused intravenously over 10 minutes X 3 ( if needed) in 30 minutes Pediatric: 3 to 5 mL/kg of 3 % saline is the suggested initial therapy For mild to moderate symptoms : Adult: 3% saline infused at 0.5-2 mL / kg / h, with a low risk of herniation Pediatric: 6 to 8 mEq/L over 24 hours (The rate of correction need not be restricted in patients with true acute hyponatremia, nor is relowering of excessive corrections indicated, however, if there is any uncertainty as to whether the hyponatremia is chronic versus acute, then the limits for correction of chronic hyponatremia should be followed)
Chronic hyponatremia	Asymptomatic: Primary management ‡ Mild to moderate symptoms : With intracranial pathology:100 mL bolus of 3 % saline x 2 (to a total dose of 300 mL) in 30 minutes Without intracranial pathology: Severe hyponatremia (< 120 mEq/L): 3 % saline at 15 to 30 mL/ h + desmopressin in patients with risk of overcorrection and osmotic demyelination syndrome Mild to moderate hyponatremia (120-129 mEq/L): Primary management ‡ Severe symptoms : 100 mL of 3% saline infused intravenously over 10 minutes X 3 ( if needed ) in 30 minutes Pediatric: Treat based on the cause, 6 to 8 mEq/L over 24 hours Primary management ‡ Hyponatremic sodium deficit = Current total body water (TBW) x (desired plasma sodium - actual sodium) ( TBW= 0.6 x weight)
Management of overcorrection	Baseline Serum Na ≥ 120 mmol/L: probably unnecessary, start once limit is exceeded Baseline Serum Na < 120 mmol/L: start relowering with electrolyte-free water or desmopressin after correction exceeds 6–8 mmol/L per d

‡ Primary management:

• Treat the underlying cause of hyponatremia
• Discontinue responsible drugs unless there is no other substitute
• Treat chronic hyponatremia and SIADH with loop diuretics, oral salt tablets, urea
• Reduce intake of electrolyte-free water(IV fluid, oral intake)

Practical approach to treatment of hyponatremia

Duration of hyponatremia • Acute hyponatremia develops < 48 hours • Chronic hyponatremia > 48hours or unknown duration

Hospitalize the patients if • The patient is symptomatic regardless of duration • Serum sodium < 125 mEq/L • Acute hyponatremia

Chronic

Acute

Is the patient symptomatic ( Whether mild, moderate, severe)

Hospitalize the patient and check for symptoms of hyponatremia ( Whether mild, moderate, severe)

Asymptomatic but serum Na < 120 mEq/L

Symptomatic patients must be admitted

No symptoms

Are the symptoms severe?

Recheck serum Na if the patient is hyponatremic ( incase of water diuresis autocorrectiom may happen

Yes

Yes

Yes

No

No

Manage the patient in the hospital • Primary management ‡ • Monitor serum Na every 4 hours to ensure appropriate rate of correction ≤ 8 mEq/L in 24 hours

Therapy • 100 ml bolus of 3% saline,repeat as needed if symptoms persist • Monitor serum Na hourly till it is increased by 4 to 6 mEq/L • Primary management‡

• Primary management ‡ • Monitor serum Na every 4 hour (Na rise ≤ 8 mEq/L in 24 h)

If no, Primary management ‡

Yes

Is there any history of intracranial pathology?Trauma, surgery, hemorrhage, neoplasm, SOP

Treatment • Monitor serum Na hourly till it is increased by 4 to 6 mEq/L • Further decline in serum Na means delayed water absorbtion • If serum Na declines give 50ml bolus of 3% saline • Primary management‡

No

Yes

Is the serum Na < 120 mEq/L?

Yes

No

Is the hyponatremia due to self-induced water intoxication?

• Primary management ‡ • Monitor serum Na every 6-12 hours

Yes

No

Therapy • Primary management ‡ • Monitor serum Na every 6-12 hours

Is the patient hypervolemic/edematous (CHF,RF,cirrhosis)

Yes

No

Treatment • Primary management ‡ • Infusion of 3% saline at the rate of 15-30 ml/hour plus IV furosemide(40 mg or higher)twice daily • Monitor serum Na frequently to adjust rate of furosemide and saline to achieve 4-6mEq/L rise in serum Na • Discontinue regimen when serum Na is at least 125 mEq/L

Is the cause of hyponatremia reversible? True hypovolemia adrenal insufficiency transient SIADH

No

Yes

Evaluate the risk for osmotic demyelination syndrome • Serum Na ≤ 105 mEq/L • Associated hypokalemia • Alcoholic patient • Malnourished patient • Advanced liver disease

No

Yes

Treatment • Primary management ‡ • Infusion of 3% salin at 15-30 ml/hour • Monitor serum Na to achieve rate of correction 4-6 mEq/L • Discontinue regimen when serum Na is at least 125 mEq/L

Treatment • Infusion of 3% saline at 15-30 ml/hour plus IV or subcutaneous desmopressin 1 to 2 mcg every 6-8 hours • Monitor serum Na to achieve rate of correction 4-6 mEq/L • Discontinue regimen when serum Na is atleast 125 mEq/L • Primary management ‡

‡ Primary management:

• Treat the underlying cause of hyponatremia
• Discontinue responsible drugs unless there is no other substitute
• Treat chronic hyponatremia and SIADH with loop diuretics, oral salt tablets, urea
• Reduce intake of electrolyte-free water(IV fluid, oral intake)

Vaptan Drugs

The “vaptan” class of drugs contains a number of compounds with varying selectivity for ADH receptors, several of which are either already in clinical use or in clinical trials.

Unselective (mixed V1A, V2):

• Conivaptan

V1A selective:

• Relcovaptan

V1B selective:

• Nelivaptan

V2 selective:

• Lixivaptan

• Mozavaptan

• Satavaptan

• Tolvaptan

Name	Characteristics
	Receptors	Route of administration	Urine volume	Urine osmolality	Sodium excretion in 24 hours	Dosage
Conivaptan	V1a/V2	IV	↑	↓	↔	20 mg loading dose followed by a continuous infusion of either 40 or 80 mg/day for four days
Lixivaptan	V2	Oral	↑	↓	↔ at low dose ↑ at high dose
Satavaptan	V2	Oral	↑	↓	↔
Tolvaptan	V2	Oral	↑	↓	↔	15 mg once daily; after at least 24 hours, may increase to 30 mg once daily to a maximum of 60 mg once daily titrating at 24-hour intervals to desired serum sodium concentration. Avoid fluid restriction during the first 24 hours of therapy. Do not use for more than 30 days due to the risk of hepatotoxicity

The V2-receptor antagonists tolvaptan and conivaptan allow excretion of electrolyte free water and are effective in increasing serum sodium in euvolemic and hypervolemic hyponatremia.

Cautions for use Vaptans in hyponatremia:

• Exclude hypovolemic hyponatremia.

• Do not use in conjunction with other treatments for hyponatremia.
• Do not use immediately after cessation of other treatments for hyponatremia, particularly 3% NaCl.
• Monitor serum sodium closely (every 6-8 hours) for the first 24-48 hours after initiating treatment.
• Maintain adequate fluid intake during the first 24-48 hours of treatment; hyponatremia can correct too quickly with coincidental fluid restriction; in patients with a defective or impaired thirst mechanism ( intubated or unconscious patients), provide sufficient fluid to prevent overly rapid correction due to unopposed aquaresis.
• Increase the frequency of serum sodium monitoring and consider stopping the vaptan if there is a change or deterioration in the patient’s condition (NPO [nothing by mouth] status, intubation) that limits the ability to request, access, or ingest fluid.
• Severe, symptomatic hyponatremia should be treated with 3% NaCl, as this provides a quicker and more certain correction of serum sodium than vaptans.

• Currently, there are insufficient data for use of vaptans in severe asymptomatic hyponatremia (serum sodium <120 mmol/L)—use vaptans with caution and with more frequent monitoring in these patients.

• If overcorrection occurs, consider re-lowering the serum sodium to safe limits (see Managing Excessive Correction of Chronic Hyponatremia).

Contraindicated medications

Hyponatremia is considered an absolute contraindication to the use of the following medications:

• Acetazolamide

Hypovolemic hyponatremia is considered an absolute contraindication to the use of the following medications:

• Tolvaptan
• Conivaptan

• Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
• Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
• Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
• Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Disease Name

• 1 Stage 1 - Name of stage
  • 1.1 Specific Organ system involved 1
    • 1.1.1 Adult
      • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
      • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
      • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
      • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
      • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
      • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
    • 1.1.2 Pediatric
      • 1.1.2.1 (Specific population e.g. children < 8 years of age)
        • Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
        • Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
        • Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
      • 1.1.2.2 (Specific population e.g. 'children < 8 years of age')
        • Preferred regimen (1): drug name 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
        • Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
  • 1.2 Specific Organ system involved 2
    • 1.2.1 Adult
      • Preferred regimen (1): drug name 500 mg PO q8h
    • 1.2.2 Pediatric
      • Preferred regimen (1): drug name 50 mg/kg/day PO q8h (maximum, 500 mg per dose)

• 2 Stage 2 - Name of stage
  • 2.1 Specific Organ system involved 1

    Note (1):

    Note (2):

    Note (3):

    • 2.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
        • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
        • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
      • Oral regimen
        • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
        • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
        • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
        • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
        • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
        • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
    • 2.1.2 Pediatric
      • Parenteral regimen
        • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
        • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
        • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '(Contraindications/specific instructions)'
      • Oral regimen
        • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
        • Preferred regimen (2): drug name (for children aged ≥ 8 years) 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
        • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
        • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
  • 2.2 'Other Organ system involved 2'

    Note (1):

    Note (2):

    Note (3):

    • 2.2.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
        • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
        • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
      • Oral regimen
        • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
        • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
        • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
        • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
        • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
        • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
    • 2.2.2 Pediatric
      • Parenteral regimen
        • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
        • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
        • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
      • Oral regimen
        • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
        • Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
        • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
        • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)